If you are asking whether Johnson & Johnson at around US$227.79 is still a reasonable entry or more of a hold for now, you will want to look closely at what the current valuation is really telling you.

Over the last year the stock has recorded a 50.2% return, with a 9.9% return year to date, alongside a 0.7% move over the past week and a 5.3% decline across the last month, which together give you a mixed picture of recent sentiment.

Recent headlines around Johnson & Johnson have focused on broad business updates and ongoing developments in its healthcare portfolio, which help frame why the share price has not moved in a straight line. These stories give useful context for thinking about whether the current price fairly reflects the risks and opportunities that investors are weighing.

On Simply Wall St's 6 point valuation checklist Johnson & Johnson scores a 3 out of 6. Next you will see how that score stacks up across different valuation methods, and then finish with a way to look at value that can give you even more context than the usual ratios and models.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes expected future cash flows and then discounts them back to today to estimate what the entire business could be worth right now.

For Johnson & Johnson, the latest twelve month Free Cash Flow is about US$17.0b. Using a 2 Stage Free Cash Flow to Equity model, analysts provide explicit forecasts out to 2030, with Simply Wall St extrapolating further to build a ten year path of cash flows. By 2030, projected Free Cash Flow is US$35.9b, with the later years in the model based on estimated growth rates rather than direct analyst forecasts.

When all of those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about US$376.56 per share. Against a recent share price of about US$227.79, the DCF output points to roughly a 39.5% discount, which indicates that, on this cash flow view, the market price sits well below the modelled value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 39.5%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Johnson & Johnson Price vs Earnings

For a profitable company like Johnson & Johnson, the P/E ratio is a useful way to link what you pay for each share to the earnings that back it. It gives you a quick sense of how many dollars investors are currently paying for each dollar of earnings.

What counts as a normal or fair P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually point to a lower one.

Johnson & Johnson currently trades on a P/E of 26.06x. That sits above the Pharmaceuticals industry average of 15.82x and the peer average of 22.27x. This suggests investors are willing to pay more than they do for many sector peers. Simply Wall St’s Fair Ratio for Johnson & Johnson is 29.51x, which is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margin, market cap and company specific risks.

The Fair Ratio can be more informative than a simple peer or industry comparison because it aims to adjust for those business characteristics. With the current P/E at 26.06x versus a Fair Ratio of 29.51x, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier the article mentioned that there is an even better way to think about valuation, and that is where Narratives come in, giving you a simple way to connect your view of Johnson & Johnson’s business to a financial forecast and then to a Fair Value that you can compare directly with the current share price.

A Narrative is essentially your story about a company written in numbers and plain language, where you spell out assumptions for future revenue, earnings, margins and a Fair Value estimate, then explain the reasoning behind them so the figures are not just abstract ratios.

On Simply Wall St, Narratives sit inside the Community page and are designed to be easy to use, so you can pick a view that fits how you see Johnson & Johnson rather than relying only on headline multiples like P/E or a single DCF model.

Because each Narrative links assumptions to a Fair Value, it can help you decide whether the current price looks high or low relative to that view, which is a useful input when you are weighing up whether to add, trim or simply watch a position.

Narratives also update as new information appears in the data set, for example when fresh earnings, guidance or news about litigation and product pipelines are incorporated into community models, so the Fair Value and supporting story stay aligned with the latest inputs rather than going stale.

The Johnson & Johnson Narratives already published on Simply Wall St show this range clearly, with Fair Values spanning from about US$133 on the cautious end up to around US$265 on the optimistic side, reflecting very different expectations for revenue growth, profit margins and future P/E multiples.

For Johnson & Johnson, however, we will make it really easy for you with previews of two leading Johnson & Johnson Narratives:

These sit at opposite ends of the current valuation debate, so comparing them side by side can help you decide which story feels closer to your own view of the business.

Fair Value: US$252.42

Implied discount vs last close: 9.8% undervalued

Revenue growth assumption: 6.50%

• Analysts see steady revenue and margin expansion from areas like immunology, oncology and MedTech, supported by ongoing investment in manufacturing, R&D and acquisitions.
• The narrative includes continued contribution from next generation therapies and acquired assets such as Intra Cellular Therapies, while acknowledging headwinds from loss of exclusivity, tariffs and litigation.
• Consensus fair value of US$252.42 sits only modestly above the current share price. In this view, that points to Johnson & Johnson being close to fairly priced on the analysts' assumptions.

Fair Value: US$173.55

Implied premium vs last close: 31.2% overvalued

Revenue growth assumption: 6.30%

• This narrative sees value in the diversified drug pipeline and post Kenvue focus on MedTech and pharmaceuticals, but still arrives at a fair value of about US$173.55.
• The author expects solid revenue growth and healthy profit margins over time, yet applies a lower fair P/E multiple and discounts for litigation, patent expiry and execution risk in the pipeline.
• On these assumptions, the current share price sits well above the modelled fair value. This is why this view classifies Johnson & Johnson as overvalued on a risk adjusted basis.

If these two previews help frame your thinking, the next step is to read the full Narratives and decide which assumptions about growth, margins, risk and P/E multiples line up best with how you see Johnson & Johnson.

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.